HLA class 1-transgenic mice express HLA antigen on their tissues and establish self-tolerance to the expressed monomorphic and polymorphic determinants.
second HLA-transgenic mouse expressing a different HLA molecule, a specific immune response is elicited that is focused on the determinants specified by the allelic HLA differences between donor and recipient transgenic mice. In the studies described, this has led to the production of a number of monoclonal antibodies with specificity for the HLA-Cw3 and HLA-B7 crossreactive groups of class I antigens. These results indicate that immunization of appropriate transgenic strains of mice with murine cells expressing a different HLA allelic transgene should permit the generation of monoclonal antibodies of narrow specificity against virtually any polymorphic epitope on HLA antigens.
Human tissue typing depends on reliable antisera traditionally procured from multiparous women and transfusion recipients as the main sources. Because of a growing need for standardization of HLA assays, a substitution of monoclonal antibodies (mAbs) for conventional antisera would be most desirable. Whereas it was once hoped that application of the hybridoma technique (1) would rapidly furnish the extensive panel of mAbs needed for a complete typing set, the results have not been uniformly encouraging. It is now clear that xeno-immunizations of mice with human cells or HLAexpressing mouse cells frequently yield antibodies of broad specificity for monomorphic determinants (2) that are not suitable for HLA-typing purposes. Nevertheless, occasional mAbs of narrow specificity for both class I and II allodeterminants have been so obtained, showing that in principle the repertoire of the mouse can furnish mAbs to polymorphic specificities (3) .
We have reasoned that to elicit a specific immune response to HLA allodeterminants, mice should first be made tolerant to HLA monomorphic determinants. To establish tolerance to HLA we have implanted HLA genes into the germ line of mice. The newly expressed trait is apparently accepted immunologically as "self' (4, 5) . Cross-immunization by tissue exchange between pairs of transgenic mice expressing different HLA class I antigens recreates the analogous circumstances that exist in the generation of human HLA antibodies in pregnancy and blood transfusions. Such an immunization scheme also adheres to the same principles governing alloimmunizations in the mouse, which have led to the discovery of scores of antigens and their allelic epitopes, including H-2, Ia, and the Ly antigens (6) (7) (8) . The essence of such alloimmunizations is that the recipient mouse is selftolerant to the shared antigen epitopes of a given locus but not tolerant to unique epitopes specified by the alleles. The present report demonstrates that alloimmunizations in HLA transgenic mice are successful in generating allele-specific mAbs even when the strains express class I antigens specified by different loci (e.g., locus B or C).
MATERIALS AND METHODS
Transgenic Mice. B6.Cw3 and B6x SJL.B7 transgenic mice were established according to published procedures (9, 10) and have been described in detail (4, 5, 11, 12) .
Founder and progeny mice were backcrossed serially to C57BL/6, and HLA-expressing progeny of both strains were selected by typing peripheral blood lymphocytes (PBLs) by complement-dependent cytotoxicity assay using mAb B9.12.1 (13) , which recognizes human class I heavy chains in association with murine /2-microglobulin. Results were verified by Southern blot analysis of tail DNA with a Cw3 probe (4) or B7 probe (5) .
Immunizations. Groups of B6.Cw3 mice received bilateral tail-skin grafts, one from a B6xSJL.B7 donor and the other from a syngeneic mouse (controls). Likewise, B6xSJL.B7 mice were grafted with tail skins of B6.Cw3 or B6xSJL.B7 mice. Grafts of the transgenic mouse skins were all rejected, with a medium survival time of 18 days, whereas syngeneic control grafts were accepted. Recipient mice were subsequently immunized at 2-week intervals with combined lymphocytes of spleen, lymph nodes, and thymus, injected intraperitoneally at increasing doses from 2 x 107 to 5 x 107 cells. Serum titers were monitored by cytotoxicity assays with human lymphoblastoid cells as targets (see below).
Hybridoma Production. Spleens of selected animals with high serum titers were collected and cells were fused with the X63Ag8563 myeloma cells, as described by Kohler Tables 1 and 2 and Figure 1 ). Reactivity to Cwl was also observed, albeit with a much lower binding affinity (note in Fig. 1 x2' calculated by a formula; R, correlation coefficient; P. probability. Correlation coefficients (R) were calculated by the formula R = V\iWN. The Cw3 group comprises subtypes Cw9 and CwlO. Cw3-CREG consists of Cw9 + CwlO + Cwll. Coefficients are given for the group cumulatively and for each subtype individually. In addition, correlations of the epitope defined by mAb 2F10 are also presented for Cwl and Cw3 cumulatively. The value obtained for Cwl after elimination of all Cw3-positive cell lines from the LCL panel ("tail-analysis") shows a high correlation for mAb 2F10 (R = 0.89; P = 10-a), indicating a real crossreactivity of mAb 2F10 with the Cwl antigen (see also Fig. 1 ). The B7-crossreactive group (CREG), comprising B40, B13, B27, and Bw47, as a whole and for each individual member, yielded high scores for mAb 865B11 when tested on the LCL panel. In contrast, mAb 546D8 reacts selectively with the B7 antigen, as shown by the high score on B7 and the low score for B27 (the rest of the B7-CREG were negative and are not shown). mAb 2F10 yielded a high R value for the Cw3 group but not for Cwl when tested by microcytotoxicity on the PBL panel. Similarly, mAb 865B11 reacted only with PBLs carrying the B7 antigen, other members of B7-CREG being unreactive (data not shown). The reactivity pattern indicates a broad B7 specificity, including HLA antigens of the B7-CREG: B13, B27, B40 (w60; w61), and Bw47 (19) . mAb 865B11 demonstrated excellent correlation with the B7-CREG (i.e., R = 0.90) when tested on the LCL panel. It is of interest to note that mAb 865B11 reacted with all those cell lines whose HLA-B amino acid sequences contain a glutamic acid residue at position 163 (18) , indicating that the B7-CREG epitope recognized by mAb 865B11 may be located on the a2 domain and shaped by glutamic acid. mAb 865B11 behaved as a private B7-specific antibody (R = 0.92) when tested on PBLs by microcytotoxicity (Table 1) . (20) 97 (69) 24 (26) 19 (27) Two mAbs (IgM isotopes), mAb 546D8 (anti-B7 related) and 865B11 (anti-B7 CREG), were analyzed by immunofluorescence as described in Table 2 , except that the analysis was carried out with a EPICS C cytofluorograph (Coulter) . WS, workshop number; ND, not determined.
Two other B7-related mAbs also had similar reaction patterns. The results obtained by testing on the LCL panel for mAb 546D8 are presented in Tables 1 and 3 . This antibody appears to detect a narrow B7 specificity, with no discernible crossreactivity to B27 or related antigens. An amino acid residue corresponding to the mAb 546D8 reactivity pattern could not be identified. This antibody probably recognizes a conformational epitope formed by only some B7 antigens, mAb 546D8 was unreactive with PBLs in the standard National Institutes of Health cytotoxicity assay, perhaps due to low affinity.
DISCUSSION
The premise of our study was that mice carrying HLA class I genes in their genome and expressing these in their tissues would establish self-tolerance to this class of HLA antigens. Therefore, when exposed to murine cells expressing a different HLA class I antigen, the antibody response would be restricted to epitopes that are specified by the HLA allele and that are not represented in the responder mouse. In practical terms, this regimen would preclude the production of the antibodies to the numerous monomorphic determinants that are shared by most HLA class I molecules. This was borne out by our results that demonstrated that virtually all HLA monoclonal antibodies isolated from the spleens of immunized transgenic mice showed clear patterns of segregation among the panels of target cells, although the specificities of several mAbs did not conform to presently known HLA specificities or alleles. The finding that antibodies raised in HLA-transgenic mice are overwhelmingly allospecific does not formally prove that self-tolerance to HLA was established in the responder mouse, but this would be a likely explanation for the absence of antibodies to the monomorphic determinants that are so numerous when conventional mice are immunized with HLA antigens. This explanation is reinforced by skin grafting that showed ready acceptance of syngeneic grafts and rejection of skin of an allo-HLAtransgenic mouse (4) .
At present neither the mechanism nor the cellular compartment of self-tolerance induction are known. Clonal deletion has been invoked by Nemazee and Burki (20) to explain their findings in transgenic mice expressing anti-H-2K antibody on their B cells in the absence but not in the presence of H-2K self-antigen. On the other hand, soluble selfantigens, such as H-2K (21) and hen egg lysozome (22) , failed to produce B-cell clonal deletion in transgenic mice. However, in the latter case B-cell tolerance was observed and ascribed to clonal anergy. The experiments presented here involve cell-surface-associated class I antigen and hence are more likely to be similar to experiments of Nemazee and Burki (20) , but because B-cell function is controlled by T cells, tolerance in the T-cell compartment alone or in addition to B-cell unresponsiveness is an alternative explanation worth considering.
The observation of several mAbs recognizing epitopes that do not conform with presently known HLA specificities is an important feature of mAbs raised in transgenic mice, indicating their potential for revealing uncharacterized polymorphic determinants. Our allospecific HLA mAbs were not always of narrow specificity but included several that crossreacted with many antigens (data not shown). These broad reactivities could be the result of our experimental design, which was based on the only two transgenic strains available to us, namely the B6.Cw3 and B6x SJL.B7 strains, and which necessitated immunization across an HLA locus barrier. Experiments with pairs of HLA-transgenic strains with less genetic disparity in the major histocompatibility complex should preclude alloantibodies of broad specificity.
In conclusion, our results show that cross-immunization of one HLA-transgenic mouse strain with tissues of a second strain expressing a different HLA antigen leads to formation of antibodies with narrow specificity. In studies to be published elsewhere, we found that murine cell lines transfected with HLA class I genes, such as B27, B13, and Bw47, are also suitable immunogens in HLA-transgenic mice for the production of allele-specific HLA mAbs, obviating the need for the generation of a large number of HLA-transgenic mouse strains. Since the HLA-transgenic mice used in our study do not express human 832-microglobulin, our data suggest that association with human 82-microglobulin is not a universal requirement for the conservation of allele-specific epitopes. On the other hand, some of the mAbs did not react with PBLs in microcytotoxicity assays and it is possible that doubly transgenic mice coexpressing both HLA and human /82-microglobin (12) might generate even more specific antibod-ies. In some instances, however, the specificities of the murine mAbs obtained are indistinguishable from those defined by conventional human alloantisera and thus should become useful reagents for human tissue typing. In our experience, the absence of antibodies with broad specificity to monomorphic epitopes implies that expression of class I antigen confers self-tolerance to these determinants and thus facilitates the response to polymorphic epitopes. If so, the immunization scheme described here should permit expeditious replacement of conventional class I and class II typing sera by mAbs of narrow specificity. In a broader application, the construction of appropriate transgenic strains with consequent self-tolerance should be of value for generating antibodies of narrow specificity against virtually any polymorphic antigen of humans for which antibodies of narrow specificity are sought.
